Roth Anna-Maria, Kauer-Dorner Daniela, Resch Alexandra, Schmid Andreas, Thill Marc, Niehoff Peter, Melchert Corinna, Berger Daniel, Kovács György
Interdisciplinary Brachytherapy Unit, University of Luebeck, Luebeck, Germany.
Department of Radiotherapy and Radiobiology, Medical University Vienna, Vienna, Austria.
Brachytherapy. 2014 Jul-Aug;13(4):394-9. doi: 10.1016/j.brachy.2013.09.003.
To evaluate accelerated partial breast irradiation (APBI) in patients after oncoplastic surgery for early breast cancer.
A retrospective analysis of 136 breasts of 134 patients, who received breast-conserving oncoplastic surgery for low-risk breast cancer between 2002 and 2010 in the Universities of Vienna and Luebeck followed by adjuvant APBI applying total doses of pulse dose rate of 50.4 Gy or high-dose rate (HDR) of 32 Gy over 4 days. Target volume definition was performed by the use of surgical-free margin data, related to intraoperatively fixed clip positions, pre- and postoperative imaging, and palpation.
At the time of data acquisition, 131 of 134 patients were alive. The median follow-up time was 39 months (range, 4-106 months). After high-dose rate treatment, 3 of 89 patients showed systemic progress after a mean follow-up of 47 months (range, 19-75 months) and 2 patients had a different quadrant in-breast tumor after 27 and 35 months. One patient died 7 months after treatment of unknown causes. After pulse dose rate treatment, 1 of 45 patients had a local recurrence after 42 months and 1 patient died because of another cause after 13 months. We observed mild fibrosis in 27 breasts, telangiectasia in 6, hyperpigmentation in 14 cases, and keloid formation in 1.
These preliminary results suggest the feasibility of multicatheter APBI after oncoplastic breast-conserving surgery in selected low-risk breast cancer patients; however, special attention to target volume definition is needed. Further prospective investigations with long follow-up are needed to define the real value of the procedure.
评估早期乳腺癌保乳整形手术后患者的加速部分乳腺照射(APBI)。
对2002年至2010年间在维也纳大学和吕贝克大学接受低风险乳腺癌保乳整形手术的134例患者的136个乳房进行回顾性分析,术后采用辅助APBI,脉冲剂量率总剂量为50.4 Gy或高剂量率(HDR)在4天内给予32 Gy。通过使用与术中固定夹子位置、术前和术后成像以及触诊相关的手术切缘数据来进行靶体积定义。
在数据采集时,134例患者中有131例存活。中位随访时间为39个月(范围4 - 106个月)。高剂量率治疗后,89例患者中有3例在平均随访47个月(范围19 - 75个月)后出现全身进展,2例患者在27个月和35个月后乳房内肿瘤位于不同象限。1例患者在治疗7个月后因不明原因死亡。脉冲剂量率治疗后,45例患者中有1例在42个月后出现局部复发,1例患者在13个月后因其他原因死亡。我们观察到27个乳房有轻度纤维化,6个有毛细血管扩张,14例有色素沉着,1例有瘢痕疙瘩形成。
这些初步结果表明,在选定的低风险乳腺癌患者中,保乳整形手术后多导管APBI是可行的;然而,需要特别注意靶体积定义。需要进行进一步的长期随访前瞻性研究来确定该手术的实际价值。